The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wouldn't read negativity into this DB. PYC are debt free and remain this way as unlike many on AIM they are not burdened with overly high Directors and management fees frequently linked to Directors abilities to "buy in". I would rather see performance based options and modest salaries as we move forward.
Difficult buying on Friday,let's see if that continues today ?
Morning,
Ant - very speculative I know but you do seem very educated in the field and as myself and others have mentioned your opinion is very much valued and it’s great to see.
Additional consulting contracts aside, how do you see the dosing tool potentially (if approved) rolling out.
Obviously these is the DoseMe Link/potential
Then there is The UK and Europe side.
I previously outlined my thoughts on the DoseMe connection…
Would be interested to see your view
cheers
KHJ
These 2 conferences cover 23rd to 28th April,should be a good opportunity to win new clients/contracts
Physiomics’ objective is to meet with leaders of early-stage/emerging biotech companies developing therapeutics in oncology and other indications to identify opportunities where quantitative pharmacology and PKPD modelling expertise can be applied to derisk their drug development journey.
Thanks for the link Ralph
Physiomics’ Head of Business Development, Hayley Close will be attending the event which brings together over 400 experts in the field of immuno-oncology to discuss the latest advancements in the discovery & development of cancer immunotherapies. Physiomics will be looking to engage with pharma and biotech leaders developing cancer immunotherapies to identify opportunities where PKPD and QSP modelling techniques can help inform development of the next generation of IO drugs.
Thanks for your input.
Can i ask with your background, why in your opinion have the new CEO not bought any shares yet?
Steady buying all day, and as someone else suggested, this happened last Friday, but only difference is last Friday sellers arrived at the end & carried on during the week.
Hopefully this a turnaround?
Yes Ant
Been difficult to buy for about 5 or 6 days now ( as in difficult to get quotes for 100k to 200k or goes to negotiate trade)
Thanks for this MSUK. Also on the yearly chart, the 200DMA is now rising, and the 50 has pretty much flattened out, so dare I say it (probably shouldn't) if this carries on next week, a Golden X could be on. Fingers crossed and all that, for us longies.....
About 200,000 shares seems to be the limit
I am pleased to pass on various suggestions as I do but more to see that the company has matured to a point where the present management and directors can really make a difference. I expect news soon and monitor progress closely.
Happened last Friday also - wouldn't say this is a pump and dump unless people are looking for beer money returns based on the actual volume.
How can you resist a P & D
Got to love it :)
Broken confluence (pivot) area ,2cd trend line which was 50ema too
https://invst.ly/14go5u
Also significant reduced costs moving forward as per all the recent presentations
The active recruitment drive for numerous roles would
Indicate the work load is increasing on many fronts
Ant
Would be great if you reach out directly to Peter S
In last 3mths I have had 2 queries answered promptly and Judging by his manner and enthusiasm I am sure he would be glad to talk to you ?
Can I also echo Trench123 and King h
Thankyou Ant
Welcome back newgrange
As king H says be good if traders become investors
For £1.5mln cap one gets £900k+ revenues to he hit for 2024) and a pipeline grown from £1.mlnnto £1.5mln
Recent interims saw record H1 revenues, reduced losses, growing pipeline and a new CEO drive
Gluck
Seem to do the same last Friday if I remember then fell Monday - traders looking for 0.1% lol
Steady buying today by the looks of it. Hope this translates into a higher sp!!
GLA
I have been writing an article very recently ( not published as yet) On the NHS This is an aside But clearly Dosing Regimes such as this are not only excellent news for patients but also present significant costs savings too. Drug mis-use primarily over ordering and not using cost The NHS millions each year, potential savings are enormous. So too the use of Generic Drugs which worldwide currently cost Health Service providers in excess of £400 billion a year and projected to rise to over £600 billion by 2030. The NHS has been intransigent but needs to avail itself of all the emergent technologies that diagnostic medical techniques present. As a complete aside We should also have a Government funded Generic GMP facility in the UK The savings would more than warrant its building and operation instead of making some foreign manufacturers incredibly wealthy!
Peter promosed more events as this is increasingly important for new business
The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunities. A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings
I would also like to second Trench’s Post.
Ant your contribution are brilliant and very much welcomed.
I have been invested in PYC for many many many years and the personalised dosing tool as stated numerous times could / should have huge commercial value.
I could be wrong but my understanding although there is numerous way it could be rolled out if approved that the technology would be integrated to Dosemerx and PYC would get a fee for this tech per license of which DoseMe has hundreds of thousand licenses in hospitals, surgery’s, universities and practises world wide !!!
This in mind the potential is exponential before you look at the UK (NHS) and European market
Difficult to buy today?
Ant, thanks for your excellent contributions which are most interesting and welcome
PYC have been banging the drum for personalised medicine for many years. They should be well placed to take full advantage now that the industry has finally recognised its huge potential opportunities and benefits
Https://invst.ly/14gktm
poss reversal in play upper trend line to break,buy volume to endorse